The BTD was received based on the data from the P-I/II clinical trial evaluating the safety, tolerability & efficacy of IB1351 monotx. In patients with advanced solid tumors incl. NSCLC who failed or were intolerant to SoC treatment
The results from the study demonstrated that 55 patients depicted an ORR of 50.9% & DCR of 92.7% whereas 21 patients treated at 600mg BID depicted an ORR of 61.9% & DCR of 100%. Both mDOR & PFS were not reached
IB1351 is a KRASG12C inhibitor that targets the GTP/GDP exchange by modifying the cysteine residue of KRASG12C protein. Additionally, the company expects to publish the updated study results at an upcoming medical conference in 2023
Ref: PRNewswire | Image: Innovent
Related News:- Innovent Entered into a Collaboration and License Agreement with LG Chem for Tigulixostat to Treat Gout Disease
